Home › Research › Clinical safety
Medication Causes and Treatment of Delirium in Patients With and Without Dementia
Anita Elaine Weidmann, Rut Matthíasdóttir, Guðný Björk Proppé, Ivana Tadić, Pétur Gunnarsson, Freyja Jónsdóttir. Brain and Behavior, 2025-07-01
Topic: Risk, prevention and care in population studies
Plain-language summary
Out of 3867 papers identified, 106 were included. Information about 20 different drug classes was reported. Despite a respectable quality rating, medication detail provided often lacks specificity about mechanisms of action, individual risk, dosage instructions, symptoms, and avoidable drug-drug combinations. Details on underlying mechanisms, pharmacological treatment, combinations, therapeutic alternatives, and medication associated with delirium in dementia patients were extracted. This summary offers the most detailed summary of medication-related information for delirium in patients with and without dementia to support prescribing decisions. While the detailed results can be used to support a multicomponent approach to delirium care, they also support the call for categorizing delirium into distinct etiological subgroups. The effect of medication on gut microbiome diversity and composition should be considered.
What this study adds
Evidence grade: High
This is a pooled review. This systematic review of 106 papers summarized medication-related information for delirium in patients with and without dementia, finding that medication detail often lacks specificity about mechanisms, individual risk, dosage, symptoms, and avoidable drug combinations. It supports a multicomponent approach to delirium care and calls for categorizing delirium into distinct etiological subgroups, but it does not report a treatment or cure for Alzheimer's disease.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Weidmann, A. E., Matthíasdóttir, R., Proppé, G. B., Tadić, I., Gunnarsson, P., & Jónsdóttir, F. (2025). Medication Causes and Treatment of Delirium in Patients With and Without Dementia. Brain and Behavior. https://doi.org/10.1002/brb3.70706
Vancouver
Weidmann AE, Matthíasdóttir R, Proppé GB, Tadić I, Gunnarsson P, Jónsdóttir F. Medication Causes and Treatment of Delirium in Patients With and Without Dementia. Brain and Behavior. 2025. doi:10.1002/brb3.70706. PMID: 40686036.
BibTeX
@article{weidmann2025-40686036,
author = {Weidmann, Anita Elaine and Matthíasdóttir, Rut and Proppé, Guðný Björk and Tadić, Ivana and Gunnarsson, Pétur and Jónsdóttir, Freyja},
title = {{Medication Causes and Treatment of Delirium in Patients With and Without Dementia}},
journal = {Brain and Behavior},
year = {2025},
doi = {10.1002/brb3.70706},
pmid = {40686036},
url = {https://doi.org/10.1002/brb3.70706}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Out of 3867 papers identified, 106 were included.
- Information about 20 different drug classes was reported.
- Despite a respectable quality rating, medication detail provided often lacks specificity about mechanisms of action, individual risk, dosage instructions, symptoms, and avoidable drug-drug combinations.
- Details on underlying mechanisms, pharmacological treatment, combinations, therapeutic alternatives, and medication associated with delirium in dementia patients were extracted.
- This summary offers the most detailed summary of medication-related information for delirium in patients with and without dementia to support prescribing decisions.
Why it matters
This systematic review of 106 papers summarized medication-related information for delirium in patients with and without dementia, finding that medication detail often lacks specificity about mechanisms, individual risk, dosage, symptoms, and avoidable drug combinations. It supports a multicomponent approach to delirium care and calls for categorizing delirium into distinct etiological subgroups, but it does not report a treatment or cure for Alzheimer's disease.
Study details
- Study designsystematic review
- Evidence strengthHigh
How this study scored 54/100
Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size, effect reported and studied in people because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain and Behavior) |
| Journal's citation record | 1 / 4 | Brain and Behavior: journal h-index 92 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A systematic review of all the studies on the question |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2025 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | A review of other studies — randomization is not credited here |
| Times cited | 2 / 7 | Cited 7 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.3 citations a year over 3 year(s) since 2025 |
| Impact for its field and year | 3 / 6 | Cited 5.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 7 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Freyja Jónsdóttir: h-index 6 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Universität Innsbruck: institution h-index 803 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 40686036) |
| Free to read | 2 / 2 | Free to read |
| Total | 54 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Clinical safety from nearby years
Also tagged “prevalence”
1,225 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,225 tagged studies.